Clinical Utilization of TROP2-Directed Antibody-Drug Conjugates
Medical oncologists share clinical practices for selecting and sequencing TROP2-directed antibody-drug conjugates, highlighting ideal candidates for sacituzumab govitecan or datopotamab deruxtecan.
Video content above is prompted by the following question:
- What insights and perspectives can you provide on the use of TROP2-directed antibody-drug conjugates from your practice?
T-DXd Use in HER2+ Breast Cancer Influenced by Site of Metastases and AE Monitoring
October 21st 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO discussed recent updates from the DestinyBreast03 trial and other key data on treatment for HER2+ breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
